Clinical trial
Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of…
NCT00230763 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00230763 |
|---|---|
| Title | Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure |
| Official title | Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure After A 12-Week Treatment With Latanoprost 0.005% / Timolol 0.5% Fixed Combination (Xalacom) In Previously Treated Patients With Open Angle Glaucoma Or Ocular Hypertension |
| Acronym | PREDICOM |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Glaucoma, Primary Open Angle (POAG), Ocular Hypertension |
| Intervention type | Drug, Procedure |
| Interventions | GSS questionnaire, IOP, LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION, Visual acuity |
| Enrollment | 396 |
| Start date | Sep 1, 2005 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Oct 3, 2005 |
| Last update posted | Feb 18, 2021 |
| Countries | France |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: